Acurx (ACXP) Pharmaceuticals announced its support and participation in the Inaugural Peggy Lillis Foundation Scientific Symposium, held on Friday, November 15, 2024. Acurx’s Executive Chairman, Bob DeLuccia, delivered opening remarks for the symposium which assembled experts and thought leaders from around the world to present state-of-the art updates regarding C difficile Infection, CDI, and therapeutic options. Topics covered included epidemiology, bacterial physiology, risk factors for infections, and new and emerging treatment modalities. The Symposium also included testimonials from patients who survived CDI.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx Pharmaceuticals Reports Promising Q3 2024 Results
- Acurx reports Q3 EPS (17c) vs. (24c) last year
- Acurx’s ibezapostat shows favorable effect in Phase 2b CDI trial
- Acurx’s ibezapolstat shows positive results in CDI and Anthrax
- Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection